The effect of a disease-specific supplement on the postprandial plasma glucose response in type 2 diabetic patients at baseline and after 6 and 12 weeks of supplementation.

1. Diagnosis type 2 diabetes;

2. Age > 18;

3. HbA1c between 6.5%-8.5%;

4. Anti-diabetic therapy: Metformin and/or sulfonylureas;

5. In need of nutritional support;

6. Capable of using oral drink feed supplementation;

7. On a stable and controlled anti-diabetic regime for at least one month;

8. Signed informed consent.

1. Pregnant or lactating woman or woman planning to become pregnant;

2. Usage of a disease specific nutritional supplement within past 4 weeks;

3. Concomitant therapy with systemic glucocorticoids, insulin or anti-diabetic medication other than Metformin or sulfonylureas;

4. Any acute gastrointestinal disease within 2 weeks prior to study entry;

5. Gastrectomy, gastroparesis or other gastric emptying abnormalities;

6. Acute severe heart failure, end stage liver failure or renal failure requiring dialysis;

7. Patients receiving enteral nutrition;

8. Patients with galactosaemia, fructosaemia or patients requiring a fibre free diet;

9. Drug or alcohol abuse;

10. Participation in other trials within 4 weeks of study entry.